Acthar PDUFA Date Delayed As FDA Reviews Post-Approval Commitments
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee had recommended trials on side effects, sustainability, dosing and safety for the infantile spasms indication, which the firm was concerned would be unethical.